| Followers | 8 |
| Posts | 342 |
| Boards Moderated | 0 |
| Alias Born | 09/27/2020 |
Wednesday, December 28, 2022 1:53:40 PM
IMO, the stock is being punished for misqueues by management.
I believe in the science of this drug but the Revive team simply doesn't have enough "hands", experience, persuasion, etc. to make it go faster or better.
I'm long on Bucillamine and will continue to hold my considerably large stack until there is a final outcome.
BTW, your question could be asked about many different investments at this point, it's been a rough ride in 2022!
I believe in the science of this drug but the Revive team simply doesn't have enough "hands", experience, persuasion, etc. to make it go faster or better.
I'm long on Bucillamine and will continue to hold my considerably large stack until there is a final outcome.
BTW, your question could be asked about many different investments at this point, it's been a rough ride in 2022!
Bullish
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
